KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bausch Health Companies (BHC) Shares Outstanding (2016 - 2025)

Bausch Health Companies (BHC) has disclosed Shares Outstanding for 15 consecutive years, with $370.5 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 0.73% to $370.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $370.5 million through Dec 2025, up 0.73% year-over-year, with the annual reading at $370.5 million for FY2025, 0.73% up from the prior year.
  • Shares Outstanding hit $370.5 million in Q4 2025 for Bausch Health Companies, roughly flat from $370.5 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $370.5 million in Q4 2025 to a low of $358.1 million in Q1 2021.
  • Historically, Shares Outstanding has averaged $364.5 million across 5 years, with a median of $364.5 million in 2023.
  • Biggest five-year swings in Shares Outstanding: rose 1.18% in 2021 and later rose 0.64% in 2023.
  • Year by year, Shares Outstanding stood at $359.4 million in 2021, then grew by 0.7% to $361.9 million in 2022, then increased by 0.91% to $365.2 million in 2023, then grew by 0.72% to $367.8 million in 2024, then grew by 0.73% to $370.5 million in 2025.
  • Business Quant data shows Shares Outstanding for BHC at $370.5 million in Q4 2025, $370.5 million in Q3 2025, and $369.7 million in Q2 2025.